An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of VXA-A1.1 by Delivery Directly to the Ileum Using the InteliSite Companion Capsule in Healthy Adult Males
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2014
Price : $35 *
At a glance
- Drugs VXA-A1-1 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Acronyms ICC H1
- Sponsors Vaxart
- 09 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Jan 2014 Planned End Date changed from 1 Feb 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 28 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.